Good continued growth for middle of summer when doc's and patients on vacation and/or not focusing on
discretionary office visits. Mid-late Sept after Labor Day and when Kowo reps will have had 6 months of calls made (which is what AMRN management says it takes) we'll see accelerated growth in scripts
Agree. Decent script #'s for height of summer vacations for MD's and patients who have better thing's to do than schedule doc appointments. AMRN/Kowa sales reps have to contend with this as well
(MD's not around). In CC, AMRN said it takes about 6 months for Kowa to get the initial calls going and then have the MDs actually start writing the scripts. After Labor Day, we should see # really starting to accelerate.
I like focus on increasing priority and strategic options outside US: Regulatory hurdles are less onerous and with Ireland domicile, AMRN can very quickly get traction with expanded Anchor indication in Europe and internationally outside US. Plus being more valuable to a potential BP acquirer.
In today's (8/12/14) Journal editorial section they review a new book: " Innovation Breakdown, How FDA & WS Cripple Medical Advances". The books narrative is strikingly similar to AMRN in focusing on the case of MELA Sciences that was also completely lead on by the FDA and then completely blind sided by advisory panel, & personal whims of specific FDA hierarchy which denied the public access to a safe and effective medical technology (Melafind) for years. FDA agreed they met all end points in clinical trails etc. Out of the blue FDA issued non-approval letter with no good cause. Stock got slammed, lives were severely harmed (Potential patients, employees and investors). In the end the president Dr.Gulfo went public with a citizens petition to the FDA commissioner directly requesting a review of MelaFinds case, congress got on the case, too, and FDA eventiually reversed itself and approved it...but after a lot of damage had already been done. In reading the review, you could easily substitute Amarin/Vascepa for Mela Sciences/MelaFind.
The sell off in the markets is good for AMRN. A lot of $ coming out of the high flyers from the last year will find it's way to the few stocks like AMRN that have seriously lagged, but have very good risk reward profiles right now
Right, the 1st Amendment challenge is a pretty low bar for AMRN to win, , very high for FDA to overcome and to deny them. AMRN simply wants to assert heir right to express scientific fact
In their conference call, GSK mentioned declining sales in their core businesses, but specifically mentioned two: their Advair respiratory market, and that they were hit by generic competition to Lovaza. If the generic competition hurts GSK, the pain is just beginning as Vascepa's traction accelerates the rest of this year.
Vascepa: cheaper, more effective and safer than Lovaza and generics.
Good thorough analysis...but lays more blame on Theo when decisions he cites were really under Joe Z
Awesome! Cleveland attracting top talent this week.. Republicans announce their next convention in Cleveland, and now LeBron announces going with the flow
Jefferies notes the stubbornness of the FDA. I suggest the FDA heed the words of John Adams: "Facts are stubborn things. Whatever may be our inclinations or dictates of our passions, they cannot alter the state of
facts and evidence" The NEJM article yesterday points to and reinforced where the facts and evidence lie
I would have expected them to be off more given holiday week. Not bad. Now new month and Kowa starting to kick in.